Physician profile
Damon K Curtis
NPI 1063895456
$10,442.02
in general payments reported to CMS, 2019-2025
25 companies · $1,948 in 2025
The $1,948 reported for 2025 was more than what 92% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,827 · 2022: $2,177 · 2023: $1,592 · 2024: $1,898 · 2025: $1,948.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,128 · Education: $310.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,128.45 |
| Education | $310.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,259.35 | 2021-2025 | |
| Janssen Biotech, INC. | $1,841.87 | 2021-2025 | Tremfya, Stelara, Simponi |
| Novartis Pharmaceuticals Corporation | $832.67 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $792.83 | 2023-2025 | Sotyktu |
| Leo Pharma INC. | $714.05 | 2021-2025 | Adbry, Anzupgo |
| Lilly USA, LLC | $644.21 | 2021-2025 | Taltz, Olumiant, Zepbound |
| Regeneron Healthcare Solutions, INC. | $552.71 | 2021-2025 | Dupixent, Libtayo |
| Ucb, INC. | $522.04 | 2021-2025 | Bimzelx, Cimzia |
| Incyte Corporation | $433.11 | 2021-2025 | Opzelura |
| Genzyme Corporation | $357.89 | 2021-2025 | |
| Amgen INC. | $223.41 | 2021-2022 | |
| Pfizer INC. | $154.28 | 2021-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $149.78 | 2021-2025 | Jublia, Siliq, Cabtreo |
| Arcutis Biotherapeutics, INC. | $144.41 | 2025 | Zoryve |
| Sun Pharmaceutical Industries INC. | $122.59 | 2021-2024 | Winlevi, Absorica Ld |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $119.44 | 2023-2024 | Vtama |
| Janssen Scientific Affairs, LLC | $103.82 | 2021 | |
| Organon LLC | $100.61 | 2024-2025 | Vtama |
| Strata Skin Sciences, INC. | $83.15 | 2023-2025 | Xtrac |
| Biofrontera INC. | $78.56 | 2021-2025 | Rhodoled Xl, Ameluz, Xepi |
| Galderma Laboratories, L.P. | $73.84 | 2021-2025 | Aklief |
| Verrica Pharmaceuticals INC. | $72.76 | 2024-2025 | Ycanth |
| Lnhc, INC | $23.07 | 2025 | Zelsuvmi |
| Misonix INC | $21.95 | 2021 | |
| Botanix Sb INC | $19.62 | 2025 | Sofdra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Damon Curtis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.